CALGB 50801: Phase II Trial of Response-Adapted Therapy based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
Aims: The purpose of this study is to determine if it is possible to safely reduce the total number of cycles of chemotherapy needed for Hodgkin lymphoma based on the patient's response during treatment as seen on positron emission tomography (PET) scan images. A PET scan is an imaging technique that can detect the possibility of active cancer.
Diagnosis: Bulky Stage I and II Classical Hodgkin Lymphoma
Principal Investigator: David Grinblatt, MD
IRB Approval Number: EH11-030
Sponsor: Alliance
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

E1A11 Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Verus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Aims: The purpose of this study is to discover the best combination and duration of treatment for patients with myeloma using drugs that have been recently approved for myeloma.
Diagnosis: Myeloma
Principal investigator: Jagoda Jasilec, MD
IRB Approval Number: EH16-306
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

Celgene Connect MDS/AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
Aims: There are three main purposes of this study: 1. To use the information collected to help better understand patterns for diagnosis, treatment and outcomes, including disease progression and survival. 2. To use the information to help better understand patterns for the quality of life in patients newly diagnosed with Lower-Risk, Higher-Risk, or unknown risk MDS or AML. 3. To use results of this study to provide information to help better understand the effect different treatments have on a patient’s disease and on their quality of life.
Diagnosis: Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
Principal Investigator: Lynne Kaminer, MD
IRB Approval Number: EH13-390
Sponsor: Celgene
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

E1910: A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Aims: The purpose of this study is to compare the effects, good and/or bad, the therapy blinatumomab has on your type of cancer (BCR/ABL negative ALL). This investigational drug will be added to what has traditionally been used to treat your specific sub-type of ALL. Studies are being done in ALL and other blood cancers with blinatumomab. It is hoped that blinatumomab will target your B-cell ALL and destroy these specific cells, but it has not yet been proven.
Diagnosis: BRCA/ABL negative Acute Lymphoblastic Leukemia (ALL)
Principal Investigator: Lynne Kaminer, MD 
IRB Approval Number: EH15-299
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

CIBMTR: Protocol for Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries 
Aims: The purpose of this study is to collect information on the collection of peripheral blood stem cells, transplant of stem cells, and the outcomes of patients who undergo peripheral blood stem cell transplant
Diagnosis: For patients undergoing a peripheral blood stem cell transplant
Principal Investigator: Lynne Kaminer, MD 
IRB Approval Number: EH15-249
Sponsor: National Marrow Donor Program
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

UC14-0899: Phase II Randomized Trial of Continuation of Post-Transplant Maintainence with Single-Agent Lenalidomide vs. Consolidation /Maintainence with Izaxomib-Lenalidomide-Dexamethasone in Patients with Residual Myeloma
Aims: The purpose of this study is to collect information on the combination of three treatments (Izaxomib-Lenalidomide and Dexamethasone)on the collection of peripheral blood stem cells, transplant of stem cells, and the outcomes of patients who undergo peripheral blood stem cell transplant
Diagnosis: For patients undergoing a peripheral blood stem cell transplant
Principal Investigator: Jagoda Jasielec, MD 
IRB Approval Number: EH16-051
Sponsor: University of Chicago
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

Astellas 2215-CL-0301: A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation
Aims: The purpose of this study is to see if a medicine called ASP2215 is safe and effective in treating AML that has come back or not responded to previous therapy if you have a gene mutation called FLT3 mutation.
Diagnosis: Acute Myeloid Leukemia
Principal Investigator: David Grinblatt, MD 
IRB Approval Number: EH16-391
Sponsor: Astellas Pharma Global Development, Inc. 
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes 

Celgene AG221-AML-004: A Phase  3, Multicenter, Open-Label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects with Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation
Aims: The purpose of this study is to see if AG-221 is safe and effective in treating AML compared to commonly used treatment options.
Diagnosis: Acute Myeloid Leukemia
Principal Investigator: Lynne Kaminer, MD 
IRB Approval Number: EH16-185
Sponsor: Celgene Corporation
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes